Clinical Research Programs at Pacific Shores Medical Group
Click on diagnosis for more information or Call Irene at 562-590-0345 Ext. 266
| ANEMIA | |
| ANTI-NAUSEA | |
| BONE METASTASES* | |
| BREAST CANCER NEW | |
| prevention adjuvant metastatic 1st line metastatic 2nd/3rd line |
|
| COLON AND RECTAL CANCER | |
| adjuvant metastatic 1st line metastatic 2nd/3rd line |
|
| ESOPHAGEAL/STOMACH | |
| KIDNEY | |
| LUNG | |
| LYMPHOMA | |
| MELANOMA | |
| PANCREAS | |
| PROSTATE | |
| SOLID TUMORS | |
| THYROID | |
| * Metastatic | Cancer resulting from the spread of the primary tumor |
| **Adjuvant therapy | Anticancer drugs, hormones, radiation therapy or other medication given after surgery to prevent the cancer from coming back |
NSABP B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens |
|
NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients completing Five years of Hormonal therapy consisting of an Aromatase inhibitor (AI) or Tamoxifen followed by an Al in prolonging Disease-Free survival in Postmenopausal Women with Hormone Receptor positive Breast Cancer |
|
NSABP B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response |
|
BETH: A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment with Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab, in Patients with Stage II or Stage Ill Breast Cancer |
|
| A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin-bound Paclitaxel (Nab-Paclitaxel or Abraxane) and Lapatinib (TYKERB®) in Women who have received no more than one prior chemotherapeutic regimen in the treatment of ErbB2 Overexpressing Metastatic Breast Cancer |
|
| A Phase 1/2, Open-label Study of Neratinib (HKI-272) in combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or locally advanced Breast Cancer | |
| Back to Top | |
| ESOPHAGEAL/STOMACH | |
| A Phase II Study of Erlotinib and modified FOLFOX-6 (5-fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients with Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia | |
A Randomized Open-Label, Multicenter, Phase 2/3 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine. Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia |
|
| A Multicenter randomized double-blind phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy | |
| A Randomized, Phase Ill Trial of ABI-007 and Carboplatin® Compared with Taxol® and Carboplatin® as First-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (on Hold) | |
| A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | |
| A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma (On Hold) | |
| MULTIPLE MYELOMA | |
| PANCREAS | |
| PREVENTION NAUSEA | |
| PROSTATE | |
| A randomized multicenter phase II trial of Patupilone (EP0906) plus prednisone versus Docetaxel (Taxotere®) plus prednisone in patients with metastatic hormone refractory prostate cancer | |
| A Randomized Double-blind, Placebo Controlled Study of the Effects of Pomegrate Extract on Rising Prostate-Specific Antigen Levels in Men following Primary Therapy for Prostate Cancer | |
| SOLID TUMOR | |
| A Study to Evaluate the Relationship between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients with Advanced Malignancies from Solid Tumors | |
| A Phase Ib, Multi-Center, Open Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination with Docetaxel in Subjects with Solid Tumors (on Hold) | |
| An Open-label Treatment Extension Study of AMG 706 | |
| THYROID | |
| * Metastatic | Cancer resulting from the spread of the primary tumor |
| **Adjuvant therapy | Anticancer drugs, hormones, radiation therapy or other medication given after surgery to prevent the cancer from coming back |